TargetMol

Lorlatinib

Product Code:
 
TAR-T3061
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T3061-2mg2mg£99.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T3061-5mg5mg£116.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T3061-1mL1 mL * 10 mM (in DMSO)£121.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T3061-10mg10mg£140.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T3061-25mg25mg£189.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T3061-50mg50mg£261.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T3061-100mg100mg£405.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T3061-500mg500mg£832.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
PF-06463922 is an orally available, ATP-competitive inhibitor of the receptor tyrosine kinases, anaplastic lymphoma kinase (ALK) and C-ros oncogene 1 (Ros1), with potential antineoplastic activity.
CAS:
1454846-35-5
Formula:
C21H19FN6O2
Molecular Weight:
406.41
Pathway:
Angiogenesis; Apoptosis; Immunology/Inflammation; Tyrosine Kinase/Adaptors
Purity:
0.9993
SMILES:
c1cc(cc2c1C(=O)N(C)Cc1c(c3cc(O[C@@H]2C)c(nc3)N)c(n(n1)C)C#N)F
Target:
Apoptosis; Tyrosine Kinases; ROS; ALK; ROS Kinase

References

1. Johnson TW, et al. J Med Chem. 2014, 57(11), 4720-4744. 2. Zou HY, et al. Mol Cancer Ther. 2013, 12, A277. 3. Zou HY, et al. Mol Cancer Ther. 2013, 12, C253. 4. Sparidans R W, Li W, Schinkel A H, et al. Bioanalytical liquid chromatography-tandem mass spectrometric assay for the quantification of the ALK inhibitors alectinib, brigatinib and lorlatinib in plasma and mouse tissue homogenates[J]. Journal of pharmaceutical and biomedical analysis. 2018 Nov 30;161:136-143. 5. Spatari, Claudia, et al. Bioanalytical assay for the quantification of the ALK inhibitor lorlatinib in mouse plasma using liquid chromatography-tandem mass spectrometry. Journal of Chromatography B. 2018 Apr 15;1083:204-208. 6. Wenlong Li, Rolf W. Sparidans, Yaogeng Wang, Maria C. Lebre, Jos H. Beijnen, and Alfred H. Schinkel. Oral coadministration of elacridar and ritonavir enhances brain accumulation and oral availability of the novel ALK/ROS1 inhibitor lorlatinib [J]. European Journal of Pharmaceutics and Biopharmaceutics. 2019 Mar;136:120-130. 7. Wenlong Li, Rolf W. Sparidans, Yaogeng Wang, Maria C. Lebre, Els Wagenaar, Jos H. Beijnen, and Alfred H. P-glycoprotein (MDR1/ABCB1) restricts brain accumulation and Cytochrome P450-3A (CYP3A) limits oral availability of the novel ALK/ROS1 inhibitor lorlatinib [J]. International journal of cancer. 2018 Oct 15;143(8):2029-2038.